Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Operating Income

Operating Income at other companies

Amgen logo
AmgenAMGN
$3.51B+32.3%
Incyte logo
IncyteINCY
$697.9M+31.6%
PVL
Palvella TherapeuticsPVLA
-$14.86M-88.7%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$80.62M-26.3%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$75.61M+10.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$16.78M+124%

Segments

By segment

See full
Reportable Segment$16.43M+212%

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M—
CapEx$158.0K+103%
Free cash flow$12.5M—

Valuation

See full
Market cap$3.32B+81.4%
Enterprise value$3.4B+82.1%
P/S7.2×+0.2×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development20,35519,45350,98236,996
Selling, general and administrative82,13869,170156,214133,172
Total operating expenses113,43296,115227,919186,490
Income (loss) from operations16,429(14,611)7,340(39,140)
Other income (expense):
Interest income2,2792,0764,5544,613
Interest expense(3,406)(3,029)(7,774)(6,011)
Other income (expense), net(157)20(177)213

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s operating income?
Arcutis Biotherapeutics, Inc. (ARQT) reported operating income of $16.43M in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s operating income changed year-over-year?
Arcutis Biotherapeutics, Inc.'s operating income increased by 212.4% year-over-year, from -$14.61M to $16.43M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s operating income?
Over 3 years (2021 to 2024), Arcutis Biotherapeutics, Inc.'s operating income has grown at a -14.7% compound annual growth rate (CAGR), from -$206.53M to -$128.4M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Arcutis Biotherapeutics, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude